NUDACC Collaborations

This multicenter observational study is designed to characterize the glycemic profile of pregnancy to understand potential early indicators of dysglycemia during pregnancy and long-term sequelae. Continuous glucose monitoring technology will be central for data collection. NUDACC is the Biostatistics Research Center for this new, NIDDK-supported consortium, serving as a central leadership hub for all project coordination and data related components of the study. See the GO MOMs website for more information (www.gomomsstudy.org).

• The goal of the ancillary study Glycemic Observation Using A1C for Gestational Diabetes Diagnosis (GO A1C GDM) is to improve hemoglobin A1C (A1C)’s ability to detect hyperglycemia in pregnancy and predict associated complications by adjusting for gestational changes in red blood cell (RBC) kinetics. GO A1C GDM will use ongoing multicenter GO MOMs study measurements from continuous glucose monitoring (CGM), hemoglobin A1C, and complete blood counts (CBCs), while adding additional hematologic measurements (single cell hemoglobin and volume measurements from CBCs, reticulocyte counts, and ferritin) at each time point to make these personalized RBC adjustments. To achieve this, GO A1C GDM will use mechanistic modeling of GO MOMs data to improve A1C-based glycemia estimation for the purpose of predicting hyperglycemia-associated adverse pregnancy outcomes.
• The GO MOMs Nutrition Study is an observational substudy nested within the GO MOMs parent study. Participants will complete 6 dietary recalls via the Automated Self-Administered 24-hour (ASA24) Dietary Assessment Tool during their pregnancies. The goal is to evaluate associations between dietary carbohydrate content at <22 weeks’ gestation and maternal glycemia 24-28 weeks’ gestation and neonatal birthweight.

This ongoing NIH/NIA-funded clinical trial is designed to investigate HIW in frail, older adults and involves 10 study sites.

The ongoing QUARTET USA trial is a randomized clinical trial designed to investigate treatment of hypertension in the Federally Qualified Health Center (FQHC) Access Community Health Network in Chicago, Illinois.

The observational Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Follow-Up Study was designed to investigate associations of maternal glycemia during pregnancy with maternal glucose metabolism and child adiposity 11-14 years after delivery. HAPO Follow-Up involved oral glucose tolerance tests and physical exams in over 4800 mother-offspring pairs at 10 international study sites. Primary findings were reported in JAMA (2018), followed by multiple other publications pertaining to secondary outcomes:

• Primary Findings: Association of Gestational Diabetes With Maternal Disorders of Glucose Metabolism and Childhood Adiposity
• Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): Maternal Glycemia and Childhood Glucose Metabolism.
• Maternal glucose levels during pregnancy and childhood adiposity in the Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study.
• Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): Maternal Gestational Diabetes Mellitus and Childhood Glucose Metabolism.

The DASH Study was part of the Rapid Acceleration of Diagnostics (RADx) initiative sponsored by the NIH, and was designed to evaluate the validity and accuracy of a point-of-care PCR test for the diagnosis of SARS-CoV-2 infection in symptomatic and asymptomatic individuals. To learn more about DASH, click here.